The trademark ENVERIC was filed by Enveric Biosciences, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on October 18, 2022, and received one opposition filed on January 18, 2023 by enverque GmbH on Likelihood of confusion. the opponent was represented by Haudan, Alexander and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued January 18, 2023
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with Pharmaceutical products and preparations for the treatment of medical conditions and disorders and pharmaceutical substances for use in the prevention, treatment and management of cancer, pain, mental health disorders, cancer related distress, anxiety, depression and post-traumatic stress disorder..
The mark was filed in class 42 with following description of goods:
Pharmaceutical research services
Medical research services
Research and development services, for the development of a portfolio of psychoactive compounds and derivatives targeted for the treatment of medical conditions and disorders
Scientific and technological research and drug development in the fields of cancer, pain, mental health disorders, cancer related distress, anxiety, depression and post-traumatic stress disorder.